Huimin Du
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Huimin Du has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Liang Chen
Department of General Surgery, The PLA 901st Hospital, Hefei, China
1 shared publication- Rongrong Feng
Department of Pathophysiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China
1 shared publication - Wuqin Xu
Department of Pathology, The First Affiliated Hospital of Wannan Medical University, Wuhu, China
1 shared publication - Xiaohui Hu
Department of Pathophysiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China
1 shared publication Xiezong Hu
Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
1 shared publication- Xun Zhou
Department of Pathophysiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China
1 shared publication
Latest Publications
- 1 June 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (26) , 2626-2642
TIA1 depletion enhances CLSTN1 exon 11 inclusion to facilitate Epithelial-to-Mesenchymal transition and breast cancer metastasis
Alternative RNA splicing is a fundamental mechanism for enhancing proteomic diversity, and its dysregulation is a hallmark of cancer progression. However, the dynamic regulatory networks controlling oncogenic splicing events remain poorly understood. Our previous work identified the inclusion of CLSTN1 exon 11 as critical for the epithelial-to-mesenchymal transition (EMT). Here, we demonstrate that this splicing event promotes breast cancer metastasis by enhancing cell migration, invasion, and the generation of circulating tumor cells (CTCs) in vivo. To translate this finding into a therapeutic strategy, we developed splice-switching antisense oligonucleotides (ASOs) that effectively reverse exon 11 inclusion and suppress cancer cell migration. Furthermore, through systematic screening, we identified the RNA-binding protein TIA1 as a key suppressor of exon 11 inclusion. TIA1 inhibits EMT and metastasis, but its function is antagonized during EMT by phosphorylation mediated by the kinase DAPK3, which is upregulated in this process. This work defines a novel DAPK3-TIA1-CLSTN1 splicing axis that drives breast cancer metastasis, revealing new layers of post-transcriptional regulation and presenting promising therapeutic avenues for targeting pro-metastatic splicing. The alternative text for this image may have been generated using AI.
- 1 June 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (26) , 2626-2642
TIA1 depletion enhances CLSTN1 exon 11 inclusion to facilitate Epithelial-to-Mesenchymal transition and breast cancer metastasis
Alternative RNA splicing is a fundamental mechanism for enhancing proteomic diversity, and its dysregulation is a hallmark of cancer progression. However, the dynamic regulatory networks controlling oncogenic splicing events remain poorly understood. Our previous work identified the inclusion of CLSTN1 exon 11 as critical for the epithelial-to-mesenchymal transition (EMT). Here, we demonstrate that this splicing event promotes breast cancer metastasis by enhancing cell migration, invasion, and the generation of circulating tumor cells (CTCs) in vivo. To translate this finding into a therapeutic strategy, we developed splice-switching antisense oligonucleotides (ASOs) that effectively reverse exon 11 inclusion and suppress cancer cell migration. Furthermore, through systematic screening, we identified the RNA-binding protein TIA1 as a key suppressor of exon 11 inclusion. TIA1 inhibits EMT and metastasis, but its function is antagonized during EMT by phosphorylation mediated by the kinase DAPK3, which is upregulated in this process. This work defines a novel DAPK3-TIA1-CLSTN1 splicing axis that drives breast cancer metastasis, revealing new layers of post-transcriptional regulation and presenting promising therapeutic avenues for targeting pro-metastatic splicing. The alternative text for this image may have been generated using AI.